Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men

Journal of Clinical Pharmacology

Volumn 38, Issue 1, 1998, Pages 54-59

  Wilson, Douglas E ^a   Meikle, A Wayne ^b   Boike, Steven C ^a   Fairless, Amanda J ^c   Etheredge, Rickey C ^a   Jorkasky, Diane K ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH HOSPITAL   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; HUMAN; HYPOGONADISM; MALE; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031885951     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04377.x     Document Type: Article

References (19)

1. Snyder PJ, Lawrence DA: Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980;51:1335-1339.
2. Schulte-Beerbuhl M, Nieschlag E: Comparison of testosterone, DHT, LH, and FSH in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril 1980;33:201-203.
3. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS: Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982;37:425-430.
4. Snyder PJ: Clinical use of androgens. Annu Rev Med 1984;35:207-217.
5. Nieschlag E, Cupper HJ, Wickings EJ: Influence of sex, testicular development and liver function on the bioavailability of oral testosterone. Eur J Clin Invest 1977;7:145-147.
6. Cantrill JA, Dewis P, Large DM, Newman M, Anderson DC: Which testosterone replacement therapy? Clin Endocrinol 1984;21:97-107.
7. Foss GL, Simpson SL: Oral methyltestosterone and jaundice. Br Med J 1959;1:259-263.
8. Ishak KG: Hepatic neoplasms associated with contraceptives and anabolic steroids. Recent Results Can Res 1979;66:73-128.
9. Nadell J, Kosek J: Peliosis hepatitis: twelve cases associated with oral androgen therapy. Arch Pathol Lab Med 1977;101:405-410.
10. Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E: Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986;2:943-945.
11. Findlay JC, Place VA, Snyder PJ: Transdermal delivery of testosterone. J Clin Endocrinol Metab 1987;64:266-268.
12. Carey PO, Howards SS, Vance ML: Transdermal testosterone treatment of hypogonadal men. J Urol 1988;140:76-79.
13. Ahmed SR, Bourcher AE, Manni A, Santen RJ, Bartholomew M, Demers LM: Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab 1988;66:546-551.
14. Findlay JC, Place V, Snyder PJ: Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 1989;68:369-373.
15. Cunningham GR, Cordero E, Thornby JI: Testosterone replacement with transdermal therapeutic systems: physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 1988;261:2525-2530.
16. Furuyama S, Mayes DM, Nugent CA: A radioimmunoassay for plasma testosterone. Steroids 1970;16:415-428.
17. Chiou WL: Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978;6:539-547.
18. Schuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-680.
19. Steinijans VW, Diletti E: Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 1983;24:127-136.